[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100610220":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":30,"centralContacts":34,"locations":40,"responsibleParty":59,"collaborators":10,"id":61,"slug":62,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":65,"acronym":66,"eligibilityCriteria":67,"healthyVolunteers":68,"sex":69,"minAge":70,"maxAge":10,"enrollmentInfo":71,"targetDuration":10,"studyType":74,"phases":10,"briefSummary":75,"conditions":76,"keywords":83,"overallStatus":43,"whyStopped":10,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":98},{"fullName":5,"class":6},"City of Hope Medical Center","OTHER",[8,12,15,18,21,24,27],{"label":9,"type":10,"description":11,"interventionNames":10},"Hepatocellular Carcinoma cohort",null,"Patients diagnosed with hepatocellular carcinoma (HCC) confirmed by clinical, imaging, and\u002For histopathological criteria. Blood samples collected retrospectively from multiple international centers.",{"label":13,"type":10,"description":14,"interventionNames":10},"Cholangiocarcinoma cohort","Patients diagnosed with cholangiocarcinoma (CCA), including intrahepatic and extrahepatic subtypes, confirmed clinically and\u002For histopathologically. Blood samples collected retrospectively from multiple international centers.",{"label":16,"type":10,"description":17,"interventionNames":10},"Pancreatic Ductal Adenocarcinoma cohort","Patients diagnosed with pancreatic ductal adenocarcinoma (PDAC), confirmed by standard diagnostic criteria. Samples collected from multiple international centers.",{"label":19,"type":10,"description":20,"interventionNames":10},"Esophageal Squamous Cell Carcinoma cohort","Patients diagnosed with esophageal squamous cell carcinoma (ESCC). Blood samples collected retrospectively from international collaborating centers.",{"label":22,"type":10,"description":23,"interventionNames":10},"Gastric Cancer cohort","Patients diagnosed with gastric cancer (GC), confirmed clinically and\u002For histopathologically. Samples collected from multiple international centers.",{"label":25,"type":10,"description":26,"interventionNames":10},"Colorectal Cancer cohort","Patients diagnosed with colorectal cancer (CRC), confirmed by standard diagnostic methods. Blood samples collected retrospectively from multiple international centers.",{"label":28,"type":10,"description":29,"interventionNames":10},"Non-cancer \u002F Healthy control group","Non-cancer individuals, including healthy volunteers and patients with benign gastrointestinal conditions. Blood samples collected from international centers and matched for age and sex where possible.",[31],{"name":32,"affiliation":5,"role":33},"Ajay Goel, PhD","PRINCIPAL_INVESTIGATOR",[35],{"name":36,"role":37,"phone":38,"phoneExt":10,"email":39},"Junyong Weng, PhD","CONTACT","06263151444","juweng@coh.org",[41],{"facility":42,"status":43,"city":44,"state":45,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"City of Hope Nat Medical Ctr","RECRUITING","Duarte","California","91010","United States","US",{"type":50,"coordinates":51},"Point",[52,53],-117.97729,34.13945,{"lat":53,"lon":52},[56],{"name":32,"role":37,"phone":57,"phoneExt":10,"email":58},"626-359-8111","ajgoel@coh.org",{"type":60,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100610220","a-noninvasive-and-screening-mirna-signature-for-gastrointestinal-cancer-100610220",false,"NCT07224750","A Noninvasive and Screening miRNA Signature for Gastrointestinal Cancer","MiGIC","Inclusion Criteria:\n\n1. Adults aged 18 years or older at the time of blood sample collection.\n2. Patients with a confirmed diagnosis of one of the following gastrointestinal cancers: Hepatocellular carcinoma (HCC), Cholangiocarcinoma (CCA), Pancreatic ductal adenocarcinoma (PDAC), Esophageal squamous cell carcinoma (ESCC), Gastric cancer (GC), Colorectal cancer (CRC), Non-cancer control participants, including healthy volunteers or patients with benign gastrointestinal conditions.\n3. Availability of retrospective blood samples collected according to institutional protocols.\n4. Willingness to allow use of de-identified clinical and demographic data for research purposes.\n\nExclusion Criteria:\n\n* other active malignancies; insufficient sample quality\u002Fvolume; recent chemotherapy\u002Fradiotherapy\u002Fsurgery; any condition preventing reliable participation.",true,"ALL","18 Years",{"count":72,"type":73},1000,"ESTIMATED","OBSERVATIONAL","Gastrointestinal (GI) cancers remain a major global health burden, largely due to the lack of effective and accessible early screening strategies. Current diagnostic approaches-including endoscopy, computed tomography (CT), and magnetic resonance imaging (MRI)-are either invasive, resource-intensive, or insufficiently sensitive for detecting early-stage disease, and are therefore not suitable for population-wide screening or for simultaneously identifying multiple GI tumor types. As a result, many patients are diagnosed at advanced stages, when therapeutic options are limited and prognosis is poor.\n\nCirculating microRNAs (miRNAs) offer a promising alternative, as they are stable in peripheral blood and reflect tumor-related molecular alterations. In this study, the investigators aim to develop and validate a robust, noninvasive miRNA-based signature capable of distinguishing GI cancers from non-malignant controls. By integrating multi-cohort datasets and applying machine learning-based feature selection and predictive modeling, the investigators will construct a screening panel optimized for reproducibility, scalability, and early-stage detection. This noninvasive miRNA signature has the potential to support accessible, cost-effective, and clinically practical population-level screening for GI cancers, ultimately facilitating earlier diagnosis and improving outcomes for participants.",[77,78,79,80,81,82],"Hepatocellular Carcinoma (HCC)","Cholangiocarcinoma","Pancreatic Ductal Adenocarcinoma (PDAC)","Esophageal Squamous Cell Carcinoma (ESCC)","Gastric Cancer (GC)","Colorectal Cancer Screening",[84,85,86,87,88],"Noninvasive screening","Circulating miRNA","Machine learning","Gastrointestinal cancer","Blood-based cancer detection","2025-11-24",{"date":91,"type":92},"2025-11-26","ACTUAL",{"date":94,"type":92},"2024-06-21",{"date":96,"type":73},"2026-06-18",{"name":5,"class":6},1]